Drug Profile


Alternative Names: AGI-1096

Latest Information Update: 18 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AtheroGenics
  • Class Anti-inflammatories; Butyric acids; Phenols
  • Mechanism of Action Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 18 Apr 2013 Discontinued - Phase-I for Transplant rejection in USA (PO)
  • 08 Feb 2006 Astellas Pharma and AtheroGenics have extended their agreement to co-develop AGI 1096 for the prevention of transplant rejection
  • 08 Feb 2006 Clinical data from a media release have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top